twinks albert and birdsim piss and fuck.desi porn
nxxx.desi
xxx sex

Heterologous versus homologous COVID-19 booster vaccinations for adults: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials | BMC Medicine

Heterologous versus homologous COVID-19 booster vaccinations for adults: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials | BMC Medicine


  • WHO. COVID-19 Weekly Epidemiological Update – Edition 158. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19—1-september-2023.

  • WHO. Global COVID-19 vaccination strategy in a changing world. July 2022 Update. Available from: https://www.who.int/publications/m/item/global-covid-19-vaccination-strategy-in-a-changing-world–july-2022-update.

  • Atmar RL, Lyke KE, Deming ME, Jackson LA, Branche AR, El Sahly HM, et al. Homologous and heterologous COVID-19 booster vaccinations. N Engl J Med. 2022;386(11):1046–57.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • WHO. SAGE updates COVID-19 vaccination guidance. Available from: https://www.who.int/news/item/28-03-2023-sage-updates-covid-19-vaccination-guidance.

  • Cheng H, Peng Z, Si S, Alifu X, Zhou H, Chi P, et al. Immunogenicity and safety of homologous and heterologous prime–boost immunization with COVID-19 vaccine: systematic review and meta-analysis. Vaccines. 2022;10(5):798.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Deng J, Ma Y, Liu Q, Du M, Liu M, Liu J. Comparison of the effectiveness and safety of heterologous booster doses with homologous booster doses for SARS-CoV-2 vaccines: a systematic review and meta-analysis. Int J Environ Res Public Health. 2022;19(17):10752.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Au WY, Cheung PPH. Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis. BMJ. 2022;377:e069989.

    Article 
    PubMed 

    Google Scholar
     

  • Korang SK, Juul S, Nielsen EE, Feinberg J, Siddiqui F, Ong G, et al. Vaccines to prevent COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING VACCINE Project). Syst Rev. 2020;9(1):262.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.

  • Wohlin C, Kalinowski M, Romero Felizardo K, Mendes E. Successful combination of database search and snowballing for identification of primary studies in systematic literature studies. Inf Softw Technol. 2022;147:106908.

    Article 

    Google Scholar
     

  • Trial Sequential Analysis (TSA) [Computer program]. The copenhagen trial unit, centre for clinical intervention research, the capital region, Copenhagen University Hospital – Rigshospitalet. 2021. 2021.


    Google Scholar
     

  • DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.

    Article 
    PubMed 

    Google Scholar
     

  • Demets DL. Methods for combining randomized clinical trials: strengths and limitations. Stat Med. 1987;6(3):341–8.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Jakobsen JC, Wetterslev J, Winkel P, Lange T, Gluud C. Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Med Res Methodol. 2014;14(1):120.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Higgins JPT. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Hebel C, Thomsen AR. A survey of mechanisms underlying current and potential COVID-19 vaccines. APMIS. 2023;131(2):37–60.

    Article 
    PubMed 

    Google Scholar
     

  • Verdecia M, Kokai-Kun JF, Kibbey M, Acharya S, Venema J, Atouf F. COVID-19 vaccine platforms: delivering on a promise? Hum Vaccines Immunother. 2021;17(9):2873–93.

    Article 
    CAS 

    Google Scholar
     

  • Lee ARYB, Wong SY, Chai LYA, Lee SC, Lee MX, Muthiah MD, et al. Efficacy of COVID-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ. 2022:e068632. https://doi.org/10.1136/bmj-2021-068632.

  • Hall VG, Ferreira VH, Wood H, Ierullo M, Majchrzak-Kita B, Manguiat K, et al. Delayed-interval BNT162b2 mRNA COVID-19 vaccination enhances humoral immunity and induces robust T cell responses. Nat Immunol. 2022;23(3):380–5.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Català M, Li X, Prats C, Prieto-Alhambra D. The impact of prioritisation and dosing intervals on the effects of COVID-19 vaccination in Europe: an agent-based cohort model. Sci Rep. 2021;11(1):18812.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol. 2008;61(1):64–75.

    Article 
    PubMed 

    Google Scholar
     

  • Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Med Res Methodol. 2009;9(1):86.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Wetterslev J, Jakobsen JC, Gluud C. Trial sequential analysis in systematic reviews with meta-analysis. BMC Med Res Methodol. 2017;17(1):39.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. J Clin Epidemiol. 2008;61(8):763–9.

    Article 
    PubMed 

    Google Scholar
     

  • Castellini G, Bruschettini M, Gianola S, Gluud C, Moja L. Assessing imprecision in Cochrane systematic reviews: a comparison of GRADE and trial sequential analysis. Syst Rev. 2018;7(1):110.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Zhang Y, Ma X, Yan G, Wu Y, Chen Y, Zhou Z, et al. Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: a randomised, double-blinded, placebo-controlled, phase 2 trial. eClinicalMedicine. 2022;54:101680.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Li J, Hou L, Guo X, Jin P, Wu S, Zhu J, et al. Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial. Nat Med. 2022;28(2):401–9.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Omma A, Batirel A, Aydin M, Yilmaz Karadag F, Erden A, Kucuksahin O, et al. Safety and immunogenicity of inactive vaccines as booster doses for COVID-19 in Türkiye: a randomized trial. Hum Vaccines Immunother. 2022;18(6):2122503.

    Article 

    Google Scholar
     

  • Yong X, Liu J, Zeng Y, Nie J, Cui X, Wang T, et al. Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine. Hum Vaccines Immunother. 2023;19(3):2267869.

    Article 

    Google Scholar
     

  • Bonelli M, Mrak D, Tobudic S, Sieghart D, Koblischke M, Mandl P, et al. Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial. Ann Rheum Dis. 2022;81(5):687–94.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Mrak D, Sieghart D, Simader E, Tobudic S, Radner H, Mandl P, et al. Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial. Nat Commun. 2022;13(1):5362.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Natori Y, Martin E, Mattiazzi A, Arosemena L, Ortigosa-Goggins M, Shobana S, et al. A pilot single-blinded, randomized, controlled trial comparing BNT162b2 vs. JNJ-78436735 vaccine as the third dose after two doses of BNT162b2 vaccine in solid organ transplant recipients. Transpl Int. 2023;36:10938.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Reindl-Schwaighofer R, Heinzel A, Mayrdorfer M, Jabbour R, Hofbauer TM, Merrelaar A, et al. Comparison of SARS-CoV-2 antibody response 4 weeks after homologous vs heterologous third vaccine dose in kidney transplant recipients: a randomized clinical trial. JAMA Intern Med. 2022;182(2):165.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Sharifi Aliabadi L, Karami M, Barkhordar M, Hashemi Nazari SS, Kavousi A, Ahmadvand M, et al. Homologous versus heterologous prime-boost COVID-19 vaccination in autologous hematopoietic stem cell transplantation recipients: a blinded randomized controlled trial. Front Immunol. 2023;14:1237916.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Jin PF, Guo XL, Gou JB, Hou LH, Song ZZ, Zhu T, et al. Immunogenicity and safety of heterologous immunisation with Ad5-nCOV in healthy adults aged 60 years and older primed with an inactivated SARS-CoV-2 vaccine (CoronaVac): a phase 4, randomised, observer-blind, non-inferiority trial. Lancet Reg Health – West Pac. 2023;38: 100829.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • Corominas J, Garriga C, Prenafeta A, Moros A, Cañete M, Barreiro A, et al. Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial. Lancet Reg Health – Eur. 2023;28:100613.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Munro APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021;398(10318):2258–76.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Kaabi NA, Yang YK, Du LF, Xu K, Shao S, Liang Y, et al. Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial. Nat Commun. 2022;13(1):3654.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Rose W, Raju R, Babji S, George A, Madhavan R, Leander Xavier JV, et al. Immunogenicity and safety of homologous and heterologous booster vaccination of ChAdOx1 nCoV-19 (COVISHIELDTM) and BBV152 (COVAXIN®): a non-inferiority phase 4, participant and observer-blinded, randomised study. Lancet Reg Health – Southeast Asia. 2023;100141.


    Google Scholar
     

  • Shinkai M, Sonoyama T, Kamitani A, Shibata RY, Seki NM, Omoto S, et al. Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: an interim report of phase 2/3, randomized, observer-blinded, noninferiority study. Vaccine. 2022;40(32):4328–33.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Launay O, Cachanado M, Luong Nguyen LB, Ninove L, Lachâtre M, Ben Ghezala I, et al. Immunogenicity and safety of beta-adjuvanted recombinant booster vaccine. N Engl J Med. 2022;387(4):374–6.

    Article 
    PubMed 

    Google Scholar
     

  • Fadlyana E, Setiabudi D, Kartasasmita CB, Putri ND, Rezeki Hadinegoro S, Mulholland K, et al. Immunogenicity and safety in healthy adults of full dose versus half doses of COVID-19 vaccine (ChAdOx1-S or BNT162b2) or full-dose CoronaVac administered as a booster dose after priming with CoronaVac: a randomised, observer-masked, controlled trial in Indonesia. Lancet Infect Dis. 2023;23(5):545–55.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Leung NHL, Cheng SMS, Cohen CA, Martín-Sánchez M, Au NYM, Luk LLH, et al. Comparative antibody and cell-mediated immune responses, reactogenicity, and efficacy of homologous and heterologous boosting with CoronaVac and BNT162b2 (Cobovax): an open-label, randomised trial. Lancet Microbe. 2023;4(9):e670–82.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Costa Clemens SA, Weckx L, Clemens R, Almeida Mendes AV, Ramos Souza A, Silveira MBV, et al. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Lancet. 2022;399(10324):521–9.

    Article 
    CAS 

    Google Scholar
     

  • Roa CC, De Los Reyes MRA, Plennevaux E, Smolenov I, Hu B, Gao F, et al. Superior Boosting of Neutralizing Titers Against Omicron SARS-CoV-2 Variants by heterologous SCB-2019 vaccine vs a homologous booster in CoronaVac-primed adults. J Infect Dis. 2023;228(9):1253–62.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Ahi M, Hamidi Farahani R, Basiri P, Karimi Rahjerdi A, Sheidaei A, Gohari K, et al. Comparison of the safety and immunogenicity of FAKHRAVAC and BBIBP-CorV vaccines when administrated as booster dose: a parallel two arms, randomized, double blind clinical trial. Vaccines. 2022;10(11):1800.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Poh XY, Tan CW, Lee IR, Chavatte JM, Fong SW, Prince T, et al. Antibody response of heterologous vs homologous messenger RNA vaccine boosters against the severe acute respiratory syndrome coronavirus 2 omicron variant: interim results from the PRIBIVAC study, a randomized clinical trial. Clin Infect Dis. 2022;75(12):2088–96.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Kulkarni PS, Gunale B, Kohli S, Lalwani S, Tripathy S, Kar S, et al. A phase 3, randomized, non-inferiority study of a heterologous booster dose of SARS CoV-2 recombinant spike protein vaccine in adults. Sci Rep. 2023;13(1):16579.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Akahata W, Sekida T, Nogimori T, Ode H, Tamura T, Kono K, et al. Safety and immunogenicity of SARS-CoV-2 self-amplifying RNA vaccine expressing an anchored RBD: a randomized, observer-blind phase 1 study. Cell Rep Med. 2023;4(8): 101134.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Hannawi S, Yan L, Saf Eldin L, Abuquta A, Alamadi A, Mahmoud SA, et al. Safety and immunogenicity of multivalent SARS-CoV-2 protein vaccines: a randomized phase 3 trial. eClinicalMedicine. 2023;64:102195.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Hannawi S, Saf Eldin L, Abuquta A, Alamadi A, Mahmoud SA, Hassan A, et al. Safety and immunogenicity of a tetravalent and bivalent SARS-CoV-2 protein booster vaccine in men. Nat Commun. 2023;14(1):4043.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Toback S, Marchese AM, Warren B, Ayman S, Zarkovic S, ElTantawy I, et al. Safety and immunogenicity of the NVX-CoV2373 vaccine as a booster in adults previously vaccinated with the BBIBP-CorV vaccine: an interim analysis. Infectious Diseases (except HIV/AIDS). 2023. Available from: http://medrxiv.org/lookup/doi/10.1101/2023.03.24.23287658.

  • Tang R, Zheng H, Wang BS, Gou JB, Guo XL, Chen XQ, et al. Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial. Lancet Respir Med. 2023;S2213260023000498. https://doi.org/10.1136/bmj-2021-068632.

  • Kaabi NA, Yang YK, Liang Y, Xu K, Zhang XF, Kang Y, et al. Safety and immunogenicity of a mosaic vaccine booster against Omicron and other SARS-CoV-2 variants: a randomized phase 2 trial. Signal Transduct Target Ther. 2023;8(1):20.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     



  • Source link

    girlfriends having fun with their favorite toy.amateur girls double dong full insertion.
    pornsnake.net
    sex tube my golden pussy is not beautiful and.